Drug Controller General of India VG Somani has approved the use of Gilead Sciences Inc’s novel drug remdesivir to treat covid-19 patients, Lav Aggarwal, joint secretary in the health ministry, said on Tuesday.
Gilead’s remdesivir was earlier under trial for Ebola, but the drug could not pass clinical trials. (REUTERS)
{{^htLoading}} {{/htLoading}}
“The DCGI gave an emergency use permission for remdesivir... and this was based on evidence that was provided by the company to support its use against covid-19,” Aggawal said at a press conference.
{{^usCountry}}{{/usCountry}}
Aggarwal said further details on the protocols for use of the intravenous drug will be provided by the government in due course.
In India, Gilead has given voluntary licence for production of remdesivir to Cipla, Jubilant Life Sciences, Hetero Drugs and Mylan under a royalty-free arrangement till an alternative drug is found or until the World Health Organization removes the designation of ‘Public Health Emergency of International Concern’ for the covid-19 pandemic.
{{^htLoading}} {{/htLoading}}
{{^usCountry}}
Gilead’s remdesivir was earlier under trial for Ebola, but the drug could not pass clinical trials. However, the covid-19 pandemic has given a fresh life to the drug, which experts have said is complex to manufacture.
{{/usCountry}}
{{#usCountry}}
Gilead’s remdesivir was earlier under trial for Ebola, but the drug could not pass clinical trials. However, the covid-19 pandemic has given a fresh life to the drug, which experts have said is complex to manufacture.
{{/usCountry}}
Gilead Sciences Inc Monday said that its phase 3 clinical trial in hospitalised patients with moderate Covid-19 pneumonia showed that a five-day treatment course of remdesivir resulted in greater clinical improvement as compared to standard care alone.
Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.
Get Latest News, breaking headlines, and top India News, and today real-time updates from across the nation. Stay informed on politics, government policies, crime, Today Weather, and major developments on Hindustan Times
Get Latest News, breaking headlines, and top India News, and today real-time updates from across the nation. Stay informed on politics, government policies, crime, Today Weather, and major developments on Hindustan Times
